Neurocrine Biosciences, Inc. (NBIX)
NASDAQ: NBIX · Real-Time Price · USD
173.00
+2.12 (1.24%)
At close: Jul 20, 2026, 4:00 PM EDT
174.01
+1.01 (0.58%)
Pre-market: Jul 21, 2026, 6:04 AM EDT
Neurocrine Biosciences Stock Forecast
Stock Price Forecast
According to 29 analysts polled by S&P Global, Neurocrine Biosciences stock has a consensus rating of "Strong Buy" and an average price target of $200.24. The average 1-year stock price forecast is 15.75% higher than the current stock price, while the lowest is $170 (-1.73%) and the highest is $250.65 (+44.88%).
Price Target: $200.24 (+15.75%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Neurocrine Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 20 | 20 | 19 | 20 | 21 | 21 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 4 | 4 | 4 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 28 | 28 | 27 | 28 | 29 | 29 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy Reiterates $175 → $200 | Buy | Reiterates | $175 → $200 | +15.61% | Jul 17, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Reiterates $199 | Buy | Reiterates | $199 | +15.03% | Jul 15, 2026 |
| Truist Financial | Truist Financial | Buy Maintains $155 → $200 | Buy | Maintains | $155 → $200 | +15.61% | Jul 13, 2026 |
| BMO Capital | BMO Capital | Hold Maintains $144 → $170 | Hold | Maintains | $144 → $170 | -1.73% | Jul 13, 2026 |
| Wedbush | Wedbush | Buy Maintains $176 → $185 | Buy | Maintains | $176 → $185 | +6.94% | Jul 13, 2026 |
Financial Forecast
Revenue This Year
3.78B
from 2.86B
Increased by 32.31%
Revenue Next Year
4.48B
from 3.78B
Increased by 18.30%
EPS This Year
9.93
from 6.39
Increased by 55.41%
EPS Next Year
12.55
from 9.93
Increased by 26.33%
EPS and Forward PE are based on non-GAAP adjusted numbers.